




# Late Effects after Allogeneic Transplant

At the conclusion of this presentation, you should be able to:

- Understand the long-term health risks after transplantation
- Establish a proper long-term care plan with your physician
- Care for your care-giver










3


Pre-Diagnosis	Disease-Related	Treatment-Related
Hypertension	Bone damage	Heart disease
Hyperlipidemia	Malnutrition	Second cancers
Diabetes	Muscle loss	Ovarian failure
Obesity	Organ damage	Osteoporosis
		Cataracts
		Skin damage
		Depression
		Fatigue
Such individuals come to tr	ore common in older indivic ansplantation with pre-exist nay be exacerbated by trans	ting health issues







#### 5



#### Not Just Transplant Recipients: Health Status Outcomes in Adult Survivors of Childhood Cancer

Cancer Dx	General Health	Functional Impairment	Activity Limitations	Mental Health	
All Patients	2.5x	5.2x	2.7x	1.8x	
Leukemia	2.2x	3.8x	1.8x	1.7x	
Hodgkin Disease	2.7x	2.4x	2.1x	2.0x	
Non-Hodgkin	2.3x	3.0x	2.0x	1.3x	
Central Nervous	3.5x	18.0x	4.1x	2.0x	
Wilms	1.8x	3.2x	2.0x	1.3x	
Sarcoma	2.2x	4.2x	2.3x	1.7x	
Shown are the odds i compared		times" more likely to bling. N=9535 adult			nes

EMADOWFEINIG PATERITS	Hudson et al. J Amer Med Soc 2003;290:1583-92
RMT: standt and	2023 SURVIVORSHIP SYMPOSIUM
<b>DIVI</b> infonet.org	

Health	Impairment	Limitations	Health
10.9%	12.0%	12.5%	17.2%
9.6%	9.3%	8.6%	17.5%
ase 12.7%	6.4%	17.8%	19.0%
9.6%	7.2%	9.0%	17.8%
ous 14.6%	31.7%	17.8%	19.0%
8.2%	7.7%	8.8%	14.1%
9.9%	9.8%	11.3%	16.1%
	9.6% ase 12.7% 9.6% ous 14.6% 8.2%	9.6% 9.3% ase 12.7% 6.4% 9.6% 7.2% ous 14.6% 31.7% 8.2% 7.7%	9.6%9.3%8.6%ase12.7%6.4%17.8%9.6%7.2%9.0%ous14.6%31.7%17.8%8.2%7.7%8.8%


# **Individual Patients May Have Special Needs**


- Race, sex, ethnicity, and one's "social determinants of health" will influence survivorship for both the patient and the caregiver
- Social determinants of health are:
  - Economic Stability


30 YEARS


**BMT**infonet.org

- Education Access and Quality
- Health Care Access and Quality
- Neighborhood Environment
- Social and Community Context











Incid	ence Ratio*	Risk Factors
• Any skin:	7.2x	• Skin: GvHD, TBI, younger age, race
• Thyroid:	5.8-6.6x	<ul> <li>Thyroid: Radiation, female, cGvHD, age</li> </ul>
• Oral:	7-27x	<ul> <li>Oral: Persistent GvHD, radiation therapy</li> </ul>
• Lung:	0.7-2.6x	• Lung: Tobacco use
Female breast:	0.3-2.0x	<ul> <li>Breast: Radiation, younger age</li> </ul>
• Cervix:	0.7-2.3	• Cervix: cGvHD
Colon:	05-2.2x	Colon: None reported
• Prostate:	0.5-0.7x	<ul> <li>Prostate: None reported</li> </ul>
*Compared to age-match com	ntrol	Inamoto Y, et al. Secondary solid cancer screening following hematopoietic cell transplantatio Bone Marrow Transplant. 2015;50:1013-2: 2023 SURVIVORSHIP SYMPOSIUM

	Event	10 –yr Cumulative Incidence <sup>1</sup>	Relative Risk (vs control) <sup>2</sup>	Relative Risk (3 risk factors*) <sup>2</sup>	
	Cardiovascular death	3.7%	2.7x	25.1x	
	Ischemic heart disease	3.8%	1.4x	68.0x	
	Heart failure	6.0%	2.5x	60.6x	
	Stroke	3.5%	1.3x	133.3x	
nsplant ative ri vivors	re incidence (total risk over t risk factors isk for 1096 pts vs 4352 cc >2 yrs after transplantations pres are: bypertension bio	ontrols	1. Chow EJ, ecel tra	et al. Late cardiovascular complica nsplantation. Biol Blood Marrow 1 , et al. Cardiovascular hospitalizat	Franspl. 2014;20:794-80







Time/Vaccine	3 mo	6 mo	12 mo	14 mo	18 mo	24 mo	Annually
Pneumonia	Prev 13	Prev 13	Prev 13			PPSV23	
Human Papilloma Virus			X (<26 yrs)		X (<26 yrs)		
Hepatitis B			Х		Х		
Polio			Х	Х	Х		
Tetanus/diphtheria			X (Tdap)	Х	Х		
Haemophilus			х	х	х		
Meningococcus			Х	Х			
Recomb Shingles			X (if ab pos)	X (if ab pos)			
MMR						Х*	
Varivax						Х*	
Influenza							Х


CANCER		A	GE	
	20-39	40-49	50-64	65 or older
Colon	If High Risk	Start age 45 yrs	Routine	Up to 75 yrs
Lung	None	None	Low-dose CT*	Low-dose CT*
Breast	Talk with PCP	Annual at 45 yrs	Annual to 54 yrs, then every 2 yrs	Every 2 yrs
Cervical	HPV every 5 yrs or PAP every 3 yrs	HPV every 5 yrs or PAP every 3 yrs	HPV every 5 yrs or PAP every 3 yrs	No test if normal for 10+ yrs
Prostate	None	Talk with PCP at 45 yrs	Talk with PCP	Talk with PCP


## Health Issues after HSCT Recommended Cardiovascular Health


Торіс	Recommendation
Risk Score	Variety of tools to assess 10 yr risk (ASCVD Risk Estimator Plus)
Nutrition	Discuss dietary patterns that increase risk of heart disease
Obesity	Overweight (BMI >25) increases risk
Physical activity	Aerobic physical activity lowers risk
Diabetes	Type 2: Influenced strongly by dietary pattern, physical activity, obesity
Lipids	Age and risk guidance provided for use of statin drugs
Hypertension	Target is now <120/80
Tobacco	No tobacco use is ever beneficial to health
Aspirin	Consider for patients 40-70 yrs of age
30 years	Adapted from: Arnett D, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Cardiol. 2019;74e177-e2 https://doi.org/10.1016/j.jacc.2019.03.0 2023 SURVIVORSHIP SYMPOSIU






















2007;25:1403-11. 2023 SURVIVORSHIP SYMPOSIUM


## Survivorship: Quality of Life, Recipients and Caregivers


- Female > male partners reported worse mental health, depression, cognitive dysfunction, social functioning
- Partners were similar to controls in reported general health (but better than patients)
- Partners (and patients) reported:
  - Worse sleep and sexual problems than controls,
  - Worse fatigue and cognitive dysfunction, and
  - · Worse impairments in mental health and depressive symptoms
- Partners (not patients) reported:
  - Lower social support, higher loneliness, less satisfaction in partnership than
     controls
     Bishop MM, et al. Late effects of cancer and hematopoietic stem-cell transplantation on
     spouses or partners compared with survivors and survivor-matched controls. J Clin Oncol.

BMT infonet.org











2023 SURVIVORSHIP SYMPOSIUM



- National Marrow Donor Program (<u>https://www.bethematch.org/survivorship</u>)
- National Coalition of Cancer Survivors (<u>www.canceradvocacy.org</u>)
- American Cancer Society (<u>www.cancer.org</u>)
- Association of Cancer Online Resources (www.acor.org)
- Cancer Survivors Projects (www.cancersurvivorsproject.org)
- National Cancer Institute Office of Cancer Survivorship (<u>dccps.nci.nih.gov/ocs</u>)





